Navigation Links
Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
Date:6/3/2009

Sees opportunity to end abusive use of authorized generics during period of exclusivity

PITTSBURGH, June 3 /PRNewswire-FirstCall/ -- Mylan Inc.'s (Nasdaq: MYL) Chief Operating Officer Heather Bresch today testified before the U.S. House of Representatives Judiciary Subcommittee on Courts and Competition Policy concerning patent litigation settlements between branded pharmaceutical companies and generic pharmaceutical companies. During her testimony, Bresch conveyed Mylan's position that the launch of an authorized generic by brand companies during a generic company's 180-day exclusivity period undermines competition and delays timely access to high quality, affordable generic medications for patients, taxpayers, the government and businesses.

The committee's hearing, "Pay to Delay: Are Patent Settlements That Delay Generic Drug Market Entry Anticompetitive?," was called to gather information about the effects of settlements.

Bresch commented: "When it comes to settlements, Congress need look no further than the use and abuse of authorized generics by brand manufacturers. The increase in the number of patent litigation settlements in recent years is directly related to the increased use of authorized generics during the 180-day market exclusivity period. This tactic upsets the natural balance of incentives that Congress intended with its 1984 Hatch-Waxman legislation."

Bresch continued: "Congress has an opportunity to act now to ensure that timely access to affordable generics is offered to patients by restoring the true 180-day exclusivity period. This is even more profound and critical today as Congress deliberates on a regulatory pathway for life-saving generic biologics, treatments that can cost hundreds of thousands of dollars per patient per year."

A complete version o
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
2. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
3. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
4. Mylan Confirms Four First-to-File Challenges
5. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
6. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
7. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
9. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
10. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
11. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 02, 2015 Research ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:6/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/l5jcdk/genotyping_market ) has announced ... Application & by Products - Global Forecast to 2020" ... genotyping market is expected to reach $17.0 Billion in ... of 22.3% during the forecast period of 2015 to ... the availability of a range of products for wide ...
(Date:6/2/2015)... --  Hospira, Inc. (NYSE: HSP ), a ... – a global biopharmaceutical company – has received approval ... Brazil – for Remsima (infliximab), ... Brazil . The medication will be ... infliximab in 26 European countries and in ...
(Date:6/2/2015)... “Stem Cell Therapy to help dogs suffering from ... used often as an adjunct to surgery in large specialty ... aware or comfortable enough with the techniques to offer it ... for the last resort cases - when nothing else works ... paw to get around. It is an easy procedure, and ...
Breaking Biology Technology:Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 2VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 3
... ChemoCentryx, Inc. today announced positive preclinical results for its ... the American Society of Nephrology. CCR2 inhibition in diabetic ... serum markers of renal function, and hyperglycemia.  These data ... Inhibition in Diabetic Mice Results in a Rapid and ...
... Nov. 10, 2011 Sequenom, Inc. (NASDAQ: SQNM ... today announced the Company,s participation at the Lazard Capital Markets ... York City November 15-16, 2011. Harry F. Hixson, ... Director and EVP of Research and Development, will present on ...
... The report " Lung Cancer Drugs ... http://www.marketsandmarkets.com/Market-Reports/lung-cancer-drugs-market-508.html ] " analyzes and studies the major ... Browse in-depth TOC on   ... 2020). Get Free 10% ...
Cached Biology Technology:ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology 2ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology 3Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference 2MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020 2MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020 3MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020 4
(Date:5/27/2015)... 27, 2015   Codonics (codonics.com), ... and image documentation solutions and Omnicell ... automation solutions, is pleased to announce their ... Safe Label System® (SLS), an award-winning FDA ... the Omnicell Anesthesia Workstation, helps prevent medication ...
(Date:5/22/2015)... -- According to a new market research ... Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, Integrated ... Home) - Global Forecast to 2020", published by MarketsandMarkets, ... 2015 to $6.19 Billion by 2020, at a CAGR ... Tables and   43 Figures spread through 140 Pages ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. ... that its wholly owned subsidiary, 3D-ID LLC, a company ... Team Battelle for the biometrics technology portion of the ... Contract from the Department of the Army. ... products developed for government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... 2009 - Collaboration in prostate cancer translational research in ... achieved in recent years but also to streamline current ... overlaps. This was amongst the goals of the two-day ... opened today in Amsterdam, The Netherlands. "It ...
... Outstanding International Horticulturist Award from the American Society for ... recognition of her longstanding and valuable contribution to international ... award on 25 July 2009 at the annual ASHS ... co-editor of the books Genetics and Genomics of Rosaceae ...
... -- Predation is one of the most fundamental and fascinating ... predators on Earth. However, their hunting pattern is difficult to ... a result, shark predatory behavior has remained much of a ... using geographic profiling -- a criminal investigation tool used to ...
Cached Biology News:Prostate Cancer Translational Research in Europe meeting: Search for biomarkers continues 2Prostate Cancer Translational Research in Europe meeting: Search for biomarkers continues 3Geographic profiling applied to track hunting patterns of white sharks in South Africa 2
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
...
Biology Products: